白蛋白结合型紫杉醇治疗晚期复治乳腺癌的临床观察  

Clinical Observation of Albumin-bound Paclitaxel in Treatment for Advanced Breast Cancer

作　　者：陈诚[1] 许红霞[1] 梅静峰[1] 王晓华[1] 洪专[1] 

机构地区：[1]江苏省肿瘤医院,江苏南京210009

出　　处：《肿瘤学杂志》2014年第12期1027-1030,共4页Journal of Chinese Oncology

摘　　要：[目的]回顾性观察以白蛋白结合型紫杉醇为主联合化疗治疗晚期复治乳腺癌的有效性和安全性。[方法]经病理组织学检查确诊的Ⅳ期乳腺癌患者23例,接受白蛋白结合型紫杉醇为主的联合化疗方案治疗。用药1个周期后评价不良反应,2个周期后方可评价疗效。[结果]23例可评价病例中,无1例获得CR,PR 7例,SD 13例,PD 3例,客观总有效（RR）率为30.4%;疾病控制（DCR）率为87.0%。中位疾病进展时间为5.3个月,1年生存率为73.9%。主要不良反应为骨髓抑制,其中Ⅲ~Ⅳ度粒细胞减少发生率为47.8%,Ⅲ~Ⅳ度血小板下降发生率为13.0%、Ⅲ度贫血发生率为21.7%;非血液学毒性轻微,可以耐受。[结论 ]白蛋白结合型紫杉醇联合化疗治疗晚期复治乳腺癌,疗效较好,不良反应可以耐受,可以考虑作为晚期复治乳腺癌的解救化疗方案。[Purpose] To investigate the efficacy and safety of albumin-bound paclitaxel in the treatment for advanced breast cancer. [ Methods ] A total of 23 cases with breast cancer stage Ⅳ confirmed by histopathology or cytopathology were received albumin-bound paclitaxel combined with chemotherapy. The efficacy was evaluated after 2 cycles of chemotherapy, and safety was evaluated after 1 cycle. [Results] Among 23 cases,there was no CR case;PR,7 cases;SD,13 cases and PD,3 cases respec- tively. The objective response rate（RR） was 30.4% and disease control rate（DCR） was 87.0%.The medi- an progression-free survival was 5.3 months and the survival rate of one year was 73.9%. The rates of G3/4 toxicities were occurred including leukopenia （47.8%）,thrombocytopenia （13.0%）,and anemia （21.7%） respectively. Non-hemotologic toxicities were modest and tolerated. [Conclusions] Albumin- bound paclitaxel can improve and stabilize quality of life in patients with advanced breast cancer with higher efficacy,and its toxicity is tolerated.It could be considered as a therapeutic salvage treatment regimen for advanded breast cancer.

关 键 词：白蛋白结合型紫杉醇 乳腺肿瘤 化学药物治疗 

分 类 号：R737.9[医药卫生—肿瘤]